SCHEMBL6098356

SCHEMBL6098356

[CH2]Cc1ccc(-n2nc(C)c(-c3ccc(OC)cc3)c2C)cc1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PDE4D Q08499 1/20 0.47
PTGS1 P23219 3/20 0.45
PTGS2 P35354 3/20 0.45
KDM4E B2RXH2 2/20 0.44
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
OPRM1 P35372 1/20 0.43
LMNA P02545 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
SMO Q99835 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096068 0.87 CYP1A2 (0.52) CYP1A2HPGDSMN1; SMN2KDM4E
SCHEMBL6095453 0.86 CYP1A2 (0.59) CYP1A2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6095984 0.86 CYP1A2 (0.48) CYP1A2NPC1POLBHPGDRAB9A
SCHEMBL6098897 0.85 CYP1A2 (0.52) CYP1A2NPC1POLBHPGDRAB9A
SCHEMBL14439485 0.85 NPC1 (0.60) CYP1A2NPC1POLBHPGDRAB9A
SCHEMBL6096730 0.84 CYP1A2 (0.76) CYP1A2NPC1RAB9ASMN1; SMN2CYP2D6
SCHEMBL6096261 0.84 CYP1A2 (0.56) CYP1A2NPC1RAB9ASMN1; SMN2CYP2D6
SCHEMBL6098683 0.84 CYP1A2 (0.56) CYP1A2NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6097890 0.84 SMN1; SMN2 (0.55) CYP1A2SMN1; SMN2KDM4ELMNA
SCHEMBL6097575 0.83 CYP1A2 (0.56) CYP1A2NPC1POLBHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CYP1A2 670/4885NPC1 2334/4885POLB 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.